Article

Pathophysiology of persistent pulmonary hypertension of the newborn: Impact of the perinatal environment

Pôle Femme-Mère-Nouveau-né, Hôpital Jeanne-de-Flandre, CHRU de Lille, Lille, France. Electronic address: .
Archives of cardiovascular diseases (Impact Factor: 1.66). 03/2013; 106(3):169–177. DOI: 10.1016/j.acvd.2012.12.005

ABSTRACT La principale cause d’hypertension pulmonaire du nouveau-né résulte d’une vasodilatation pulmonaire insuffisante à la naissance, appelée « hypertension artérielle pulmonaire persistante du nouveau-né » (HTAPP). Ce syndrome est caractérisé par une élévation des résistances vasculaires pulmonaires, responsable d’un shunt droit-gauche par le foramen ovale et le canal artériel et d’une profonde hypoxémie. L’HTAPP est à risque vital lorsque qu’elle s’accompagne d’une défaillance circulatoire. La prise en charge nécessite un recrutement pulmonaire adéquat, l’inhalation de monoxyde d’azote et un support cardiovasculaire adapté. Néanmoins, la physiopathologie et la prise en charge sont toujours l’objet de recherches innovantes. Ainsi, de plus en plus d’arguments existent pour penser que l’environnement périnatal joue un rôle déterminant dans la genèse et l’aggravation de ce syndrome.

1 Follower
 · 
80 Views
 · 
59 Downloads
  • [Show abstract] [Hide abstract]
    ABSTRACT: With the world-wide obesity epidemic, the proportion of women entering pregnancy overweight or obese has increased significantly in recent years. Babies born to obese women are at an increased risk of respiratory complications at birth and in childhood. In addition to maternal diabetes, there are a number of metabolic changes that the fetus of an overnourished mother experiences in utero that may modulate lung development and represent the mechanisms underlying the increased risk of respiratory complications. Here, we have highlighted a series of factors associated with the intrauterine environment of an overnourished mother which may impact on fetal lung development and lead to an increased risk of complications at birth or in postnatal life. This article is protected by copyright. All rights reserved.
    Clinical and Experimental Pharmacology and Physiology 09/2013; 40(11). DOI:10.1111/1440-1681.12166 · 2.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sepsis causes neutrophil sequestration in the lung, which leads to acute lung injury (ALI). Neutrophil elastase (NE) is thought to play an important role in the pathogenesis of ALI. This study investigated whether Sivelestat, a specific NE inhibitor, can attenuate ALI induced by lipopolysaccharide (LPS). In vivo, 30 male Wistar rats were divided into three groups (n = 10 each groups) on the basis of the reagent used, which were subjected to LPS injection with or without Sivelestat treatments to induce ALI model. Lung injury was assessed by pulmonary histology, lung wet-weight to dry-weight (W/D) ratio, immunohistochemical analysis of intercellular adhesion molecule-1 (ICAM-1), the number of myeloperoxidase (MPO)-positive cells, and gene expression of ICAM-1. In vitro, pulmonary microvascular endothelial cells (PMVECs) were stimulated with LPS in the presence and absence of Sivelestat; nuclear factor-κB (NF-κB) p65 was measured by immunocytochemistry staining and Western blotting. Infusion of LPS induced lung injury, in vivo, as demonstrated by pulmonary edema with infiltration of neutrophils, the increase in lung W/D ratio, the number of MPO-positive cells and enhanced expression of ICAM-1 and ICAM-1 gene. In vitro, the significant increased release of NF-κB p65 and its subsequent translocation into the nucleus in PMVECs. In contrast, Sivelestat treatment significantly ameliorated the LPS-induced lung injury, as judged by the marked improvement in all these indices. These results indicated that inhibition of NE attenuated LPS-induced lung injury through an inhibition of the inflammatory signaling pathway, besides the direct inhibitory effect on NE.
    Apmis 02/2014; 122(9). DOI:10.1111/apm.12222 · 1.92 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Persistent pulmonary hypertension of the newborn (PPHN) is a syndrome of failed circulatory adaptation at birth, seen in about 2/1000 live born infants. While it is mostly seen in term and near-term infants, it can be recognized in some premature infants with respiratory distress or bronchopulmonary dysplasia. Most commonly, PPHN is secondary to delayed or impaired relaxation of the pulmonary vasculature associated with diverse neonatal pulmonary pathologies, such as meconium aspiration syndrome, congenital diaphragmatic hernia, and respiratory distress syndrome. Gentle ventilation strategies, lung recruitment, inhaled nitric oxide, and surfactant therapy have improved outcome and reduced the need for extracorporeal membrane oxygenation (ECMO) in PPHN. Newer modalities of treatment discussed in this article include systemic and inhaled vasodilators like sildenafil, prostaglandin E1, prostacyclin, and endothelin antagonists. With prompt recognition/treatment and early referral to ECMO centers, the mortality rate for PPHN has significantly decreased. However, the risk of potential neurodevelopmental impairment warrants close follow-up after discharge for infants with PPHN.
    Seminars in perinatology 03/2014; 38(2):78–91. DOI:10.1053/j.semperi.2013.11.004 · 2.42 Impact Factor
Show more

Full-text

Download
59 Downloads
Available from
Nov 16, 2014